纳米酶的最新进展用于治疗动脉样硬化
Zheng Zou1, Xiaojun Bi2, Huan Ma3
1Department of Neurosurgery, General Hospital of Northern Theater Command, Liaoning, 110016, People's Republic of China.
International journal of nanomedicine
|August 4, 2025
概括
纳米酶提供了一种有前途的新方法来治疗动脉样硬化 (AS),通过向炎症和氧化应激. 为了临床应用,需要进一步研究生物相容性和制造方法.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 心血管医学 心血管医学
背景情况:
- 动脉样硬化 (AS) 是一种复杂的心血管疾病,治疗选择有限.
- 目前针对AS的治疗方法面临着一些挑战,比如针对性不佳和系统性副作用.
- 具有类似酶的特性的纳米酶显示出在AS中进行多目标干预的潜力.
研究的目的:
- 审查最近纳米酶为动脉样硬化治疗的干预措施的进展.
- 讨论AS中各种纳米酶的设计,机制和治疗结果.
- 突出纳米酶在AS中的临床转化所面临的挑战和未来方向.
主要方法:
- 在动脉样硬化中纳米酶应用的综合文献综述.
- 对纳米酶设计原理,催化机制和准策略的分析.
- 在临床前AS模型中评估治疗结果.
主要成果:
- 纳米酶有效调节AS中的氧化应激,炎症和脂质代谢.
- 普鲁士蓝色,氧化,基和复合纳米酶显示出有希望的结果.
- 临床前研究表明,纳米酶干预具有显著的治疗潜力.
结论:
- 纳米酶代表了精密治疗动脉样硬化症的变革性战略.
- 关键的挑战包括生物安全,药理动力学和制造标准化.
- 未来的工作重点应该是提高临床翻译的生物相容性,特异性和可扩展性生产.
更多相关视频
相关概念视频
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Atherosclerosis I: Introduction
85
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
85
Atherosclerosis IV: Nursing Management
51
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
51
Coronary Artery Disease I: Introduction
57
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
57
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
873
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
873
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
39
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
39


